- ¥421 - 5990
- Solarbio
- 北京
- IB6780
- 2026年08月14日
企业认证
相关产品推荐更多 >
![[Tyr3]Octreotate](https://img1.dxycdn.com/p/s14/2026/0814/574/8862614766769118802.png!wh200)
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
细胞污染识别与处理全攻略：5 种常见类型+关键误区Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:-20℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:-20℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
Banoxantrone Dihydrochloride
- 库存：
999
- 供应商：
北京索莱宝科技有限公司
- CAS号：
252979-56-9
- 规格：
5mg/1mg/10mg/25mg/50mg
| 规格： | 5mg | 产品价格： | ¥940.00 |
|---|---|---|---|
| 规格： | 1mg | 产品价格： | ¥421.00 |
| 规格： | 10mg | 产品价格： | ¥1640.00 |
| 规格： | 25mg | 产品价格： | ¥3690.00 |
| 规格： | 50mg | 产品价格： | ¥5990.00 |
| CAS | 252979-56-9 |
| 英文名称 | Banoxantrone Dihydrochloride |
| 分子式 | C22H30Cl2N4O6 |
| 分子量 | 517.4 |
| 规格 | 5mg ; 1mg ; 10mg ; 25mg ; 50mg |
| 溶解性 | Soluble in DMSO/Water |
| 纯度 | ≥98% |
| 级别 | Cell Culture |
| 外观(性状) | Blue to dark blue Solid |
| 储存条件 | Powder:-20℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| 运输条件 | 冷冻运输 |
| SMILES | C[N+](C)(CCNC1=C2C(=C(C=C1)NCC[N+](C)(C)[O-])C(=O)C3=C(C=CC(=C3C2=O)O)O)[O-].Cl.Cl |
| InChIKey | SBWCPHUXRZRTDP-UHFFFAOYSA-N |
| InChI | InChI=1S/C22H28N4O6.2ClH/c1-25(2，31)11-9-23-13-5-6-14(24-10-12-26(3，4)32)18-17(13)21(29)19-15(27)7-8-16(28)20(19)22(18)30;;/h5-8，23-24，27-28H，9-12H2，1-4H3;2*1H |
| PubChem CID | 72941779 |
| 靶点 | Others |
| 通路 | Others |
| 背景说明 | Banoxantrone dihydrochloride 是一种新型的缺氧选择性细胞毒素，通过 iNOS 依赖机制选择性地杀死缺氧细胞。 |
| 生物活性 | Banoxantrone dihydrochloride is a novel bioreductive agent that can be reduced to a stable， DNA-affinic compound AQ4， which is a potent topoisomerase II inhibitor.[1-3] |
| In Vitro | Banoxantrone (AQ4N) can be reduced in a hypoxic environment to a stable DNA-affinic agent AQ4. AQ4， a potent topoisomerase II inhibitor， would be capable of damaging cells recruited into the cell cycle following radiation damage to the well-oxygenated cells of the tumor[1]. Banoxantrone shows more than 8-fold higher cytotoxicity under hypoxia than normoxia in cultures of 9L rat gliosarcoma and H460 human non-small-cell lung carcinoma cells but not for 11 other human cancer cell lines. DT-diaphorase protein levels and banoxantrone chemosensitivity are poorly correlated across the cancer cell line panel， and banoxantrone chemosensitivity is not affected by DT-diaphorase inhibitors[2]. Banoxantrone is a bis-N-oxide that is reduced via two sequential two-electron reductions to the tertiary amine， AQ4， which is a potent cytotoxic agent toward both aerobic and hypoxic cells. AQ4， but not AQ4N， intercalates in DNA with high affinity to generate a stable persistent complex that can inhibit topoisomerase II and cause DNA damage and cell death[3]. |
| In Vivo | Banoxantrone (200 mg/kg) significantly enhances the tumor growth delay caused by radiation. This occurred when radiation is administered both as a single dose (12 Gy) and in a multifraction regimen (5x3 Gy). A study of the scheduling of Banoxantrone (AQ4N) administration shows that there is a very long time period over which a maximal effect can be elicited (drug given 4 days before to 6 h after radiation). These results suggest that Banoxantrone has significant potential as a bioreductive drug[1]. The activation of banoxantrone cytotoxicity in vivo requires tumor hypoxia that is more extensive or prolonged than can readily be achieved by vasodilation or by antiangiogenic drug treatment[2]. Incorporation of banoxantrone into conventional chemoradiation protocols therefore targets both oxygenated and hypoxic regions of tumors， and potentially will increase the effectiveness of therapy. A single dose of 60 mg/kg banoxantrone enhances the response of RT112 (bladder) and Calu-6 (lung) xenografts to treatment with cisplatin and radiation therapy. Banoxantrone will increase the efficacy of chemoradiotherapy in preclinical models[3]. |
| 动物实验 | Mice[1] T50/80 tumor-bearing mice are used. These experiments are carried out when tumors reach a geometric diameter (GMD) of 6.5-9.0 mm. Banoxantrone (AQ4N) is administered as a single i.p. injection at a dose of 200 mg/kg. The drug is given 30 min before a single dose of X-irradiation of 12 Gy (300 kVp Siemens Stabilipan with a dose rate of 2.56 Gy min-1). Tumors are excised at a range of times following treatment and placed on ice. Single cell suspensions are prepared in ice-cold PBS as outlined above. Following centrifugation the cells are diluted in cold EMEM containing 10% FCS (1x106 cells/mL). An aliquot of 100 μL of this suspension is used in the comet assay. This procedure is carried out on tumors excised at various time intervals ranging from 0 to 120 h following irradiation. The results are pooled from three individual experiments. |
| 激酶实验 | Untreated T50/80 tumors (6.5-9.0 mm geometric diameter (GMD) are excised and gently disaggregated by mechanical disruption in ice-cold phosphate-buffered saline (PBS). Single cell suspensions are prepared by filtration through a 40μm mesh. These are then centrifuged and resuspended in Eagle‘s minimal essential medium (EMEM) containing 10% fetal calf serum (FCS) at a concentration of 106 cells/mL. Cells (20 mL) are placed in 125 mL rubber sealed glass bottles. These are gassed for 2 h at 37°C to provide welloxygenated conditions， i.e. 95% air/5% carbon dioxide or hypoxic conditions 95% N2/5% CO2. Banoxantrone (AQ4N) (20μM) is added for the last 90 min of this period by injection through the sealed lid. Drug is washed off and cells resuspended in fresh medium. For analysis of DNA damage， aliquots (105 cells) are processed at various times ranging from 0 to 96 h after this procedure. To evaluate the effect of maintaining the excised tumor cells in culture， samples are also maintained in the culture medium above at 37°C， 95% air/5% CO2 for 24 h. The cells， which grow in suspension， are then harvested and placed in glass bottles and the experiment outlined above is carried out. Each experiment is carried out twice and the results pooled[1]. |
| 数据来源文献 | [1]. Hejmadi MV， et al. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. Br J Cancer. 1996 Feb;73(4):499-505. [2]. Manley E Jr， et al. Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone. J Pharmacol Exp Ther. 2013 Feb;344(2):368-77. [3]. Williams KJ， et al. In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts. Mol Cancer Ther. 2009 Dec;8(12):3266-75. |
| 单位 | 瓶 |
| 表格1 | |*|1mg|5mg|10mg|$$|1mM|1.9327mL|9.6637mL|19.3274mL|$$|5mM|0.3865mL|1.9327mL|3.8655mL|$$|10mM|0.1933mL|0.9664mL|1.9327mL| |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
疟原虫 Malaria Parasites(Plasmodium)
can be used:Quinine dihydrochloride 20 mg salt/kg base given I.V. in 5% w/v dextrose or normal saline as a once-only 4 hour infusion followed, 4 hours later, by quinine dihydrochloride 10 mg salt/kg base 4-hour infusions 8 hourly.Where a syringe pump
Measuring Antioxidant Capacity Using the ORAC and TOSC Assays
by antioxidants, and the second is the total oxyradical scavenging capacity (TOSC) assay, which measures the decrease in ethylene gas production caused by the inhibition of the thermal hydrolysis of ABAP (2,2′-Azobis(2-methyl-(propionamidine) dihydrochloride
for each d12 mm coverslip, 25 µl for square coverslip and 50µl for full size coverslip• Seal the coverslip with nail polish• Store in 4 C up to 2 weeksDAPI stock• 4’, 6-Diamidino-2-phenylindole dihydrochloride hydrate (DAPI) from Sigma (Cat# D-9542), 1 mg 1mg
技术资料暂无技术资料 索取技术资料
Banoxantrone dihydrochloride
¥421 - 5990
